News
HC Wainwright & Co. Maintains Buy on Genmab, Maintains $50 Price Target
27 Mar 24
News, Price Target, Analyst Ratings
Morgan Stanley Maintains Underweight on Genmab, Maintains $32 Price Target
26 Mar 24
News, Price Target, Analyst Ratings
Analyst Ratings For Genmab
26 Mar 24
Analyst Ratings
Truist Securities Maintains Buy on Genmab, Maintains $50 Price Target
26 Mar 24
News, Price Target, Analyst Ratings
4 Analysts Assess Genmab: What You Need To Know
20 Feb 24
Analyst Ratings
Genmab Announces Initiation Of Share Buy-Back Program Of Up To 190,000 Shares; Will Start On February 15, 2024, And End On March 15, 2024
14 Feb 24
News, Buybacks
Earnings Outlook For Genmab
13 Feb 24
Earnings
Cracking The Code: Understanding Analyst Reviews For Genmab
29 Jan 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $50
29 Jan 24
News, Price Target, Analyst Ratings
What's Going On With Danish Healthcare Firm Genmab Stock?
23 Jan 24
Analyst Color, Biotech, Equities, Large Cap, News, Health Care, Reiteration, Legal, Movers, Trading Ideas, General
Genmab Announced Earlier Today That Appeal Arbitrator In Its Second Arbitration Arising Under Its License Agreement With Janssen For Daratumumab Has Denied Genmab's Appeal
22 Jan 24
News, Legal
Press releases
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
27 Feb 24
Press Releases
Genmab Announces Initiation of Share Buy-Back Program
14 Feb 24
Press Releases
Genmab Publishes 2023 Annual Report
14 Feb 24
Press Releases
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
2 Feb 24
Press Releases
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
9 Jan 24
Press Releases
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
9 Jan 24
Press Releases